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ABSTRACT
Epidermal Growth Factor Receptor (EGFR) activates a robust signalling network to 
which colon cancer tumours often become addicted. Cetuximab, one of the monoclonal 
antibodies targeting this pathway, is employed to treat patients with colorectal 
cancer. However, many patients are intrinsically refractory to this treatment, and 
those who respond develop secondary resistance along time. Mechanisms of cancer 
cell resistance include either acquisition of new mutations or non genomic activation 
of alternative signalling routes. In this study, we employed a colon cancer model 
to assess potential mechanisms driving resistance to cetuximab. Resistant cells 
displayed increased ability to grow in suspension as colonspheres and this phenotype 
was associated with poorly organized structures. Factors secreted from resistant cells 
were causally involved in sustaining resistance, indeed administration to parental 
cells of conditioned medium collected from resistant cells was sufficient to reduce 
cetuximab efficacy. Among secreted factors, we report herein that a signature of 
inflammatory cytokines, including IL1A, IL1B and IL8, which are produced following 
EGFR pathway activation, was associated with the acquisition of an unresponsive 
phenotype to cetuximab in vitro. This signature correlated with lack of response to 
EGFR targeting also in patient-derived tumour xenografts. Collectively, these results 
highlight the contribution of inflammatory cytokines to reduced sensitivity to EGFR 
blockade and suggest that inhibition of this panel of cytokines in combination with 
cetuximab might yield an effective treatment strategy for CRC patients refractory to 
anti-EGFR targeting.
INTRODUCTION
Epidermal Growth Factor Receptor (EGFR) was 
the first member of the ERBB family to be discovered, 
and later found to be directly mutated or overexpressed 
in solid tumours. The roles played by EGFR proved 
to be central in colorectal cancer patients, who often 
present an addiction to this pathway [1]. EGFR 
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signalling appears to be propagated downstream through 
multiple effectors, with a main vertical transmission 
of the signal. Nevertheless, in the last decade, the 
development of high throughput technologies described 
the ERBB family as a systemic network that follows the 
principles of network theories [2, 3], characterized by 
multiple levels of regulatory loops, namely feed-back 
and feed-forward loops [4]. The integration and often 
intertwining negative- and positive-feedback circuits 
help maintaining appropriate quantitative and dynamic 
relationships between inputs (growth factor stimuli) 
and outputs (cellular phenotype), allowing a fast and 
stable attainment of a new steady state [5]. This ensures 
that most cellular parameters stay under tight control 
within a narrow range and around a certain optimal 
level. Feedback deregulation is thus often responsible 
for diseases, hence characterization of either positive 
or negative feedback, including transcription-mediated 
processes, has been extensively investigated in the last 
decade [6, 7].
The development of neutralizing antibodies 
targeting EGFR, such as cetuximab and panitumumab, 
created a breakthrough in metastatic colorectal 
cancer (mCRC) treatment [8, 9]. EGFR antibodies in 
combination with chemotherapy prolong survival in 
subjects with mCRC and are a standard component of 
therapy of such individuals [9]. The genetic evaluation 
for KRAS and NRAS mutations currently represents the 
main clinical criterion predicting treatment efficacy, since 
mutations in these genes foresees an individual’s intrinsic 
resistance to the monoclonal antibodies [10]. However, 
unfortunately, many subjects with KRAS/NRAS wild-
type mCRC display de novo resistance, and those who 
initially respond ultimately acquire secondary resistance 
to these agents [11, 12]. All these clinical observations 
require a deeper understanding of the mechanisms 
involved in the failure to intercept EGFR, which leads 
to drug resistance. Thus, mechanistic studies in this 
direction will endorse the development of more effective 
therapeutic approaches.
Resistance to EGFR blockade may have a genetic 
basis, including oncogenic activation of downstream 
or parallel signalling pathways that substitute for 
EGFR inhibition [13], but may also rely on plastic, 
reversible traits induced by drug pressure [14], such as 
compensatory activation of biochemical feedback circuits 
and transcriptional modifications [15-17]. In this study we 
employed CRC cell line to explore the plastic phenotype 
of cellular adaptation to prolonged cetuximab treatment. 
We found that resistance to EGFR targeting drugs results 
in the up-regulation of a signature of inflammatory 
cytokines, namely IL1A, IL1B and IL8. The association 
between reduced sensitivity to anti-EGFR antibodies and 
increased expression of this inflammatory signature was 
confirmed in patients’ data and specimens.
RESULTS
Long-term exposure to antibody- or small 
molecule-mediated EGFR inhibition leads to the 
emergence of cross-resistant cell lines
We established cetuximab-resistant cells from 
the human colorectal cell line Caco-2, which is wild-
type for KRAS and BRAF, and dependent on EGFR as 
a mitogenic stimulus, as previously characterized in 
our laboratory [18]. Caco-2 cells were made resistant 
to cetuximab (CX) or the EGFR small-molecule 
inhibitor gefinitib (GB), by continuous exposure over 
six months to increasing concentrations of the drugs, 
ranging from 10 ng/ml to 20 μg/ml in the case of CX 
and from 1nM to 10μM for GB. Notably, the cells 
were kept under CX (2 μg/ml) or GB treatment (1μM), 
while propagating. We first confirmed resistance, by 
measuring cell growth using the Alamar assay. Caco-2 
parental cells and CX or GB resistant cells, hereinafter 
referred as parental, CXR and GBR, respectively, were 
treated with increasing concentrations of CX for 72-96 
h and their proliferation was compared to cells treated 
with vehicle only, DMSO or PBS (Figure 1A). While 
parental cells displayed growth inhibition under CX 
treatment, with maximal inhibition achieved at 1 to 
5 μg/ml of the antibody, the resistant sub-line CXR 
displayed undisturbed viability under CX treatment, 
confirming acquired resistance. Similarly, the GBR 
cells, which exhibited resistance to GB treatment, 
remained fully viable under CX treatment, suggesting 
a cross-resistance of GB-resistant cells to CX 
(Figure 1A).
We next performed a long-term clonogenic assay, 
by seeding a very low number of cells in twelve well 
plates with the indicated treatments. After 10 days, the 
cells were fixed and stained with crystal violet, and 
clonogenic cell growth was evaluated by measuring 
the portion of covered area of the plate. In this assay, 
parental cells displayed a ~50% and ~70% growth 
inhibition upon CX and GB treatment, respectively 
(Figure 1B, C). In contrast, no change in clonogenic 
cell growth was detected in CXR and GBR cells, 
supporting the previous observation of an acquired 
cross-resistance. Finally, we performed the sequence 
analyses of KRAS exon 2, codon 12, in order to test 
whether acquisition of KRAS mutation could explain 
the observed resistant phenotype. Interestingly, none 
of the CXR or GBR cells displayed acquired mutation 
(Figure 1D).
Overall, our Caco-2 in vitro model suggests a 
mechanism of resistance to EGFR targeted therapies 
shared by monoclonal antibodies and small tyrosine 
kinase inhibitors, independent from acquisition of KRAS 
mutation.
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Resistant cells display anchorage-independent 
growth as spheroids
The ability to grow in suspension is a hallmark 
of the neoplastic phenotype. Notably, only a small 
percentage, about 0.5% of Caco-2 parental cells displayed 
the ability to grow in suspension and form spheroid-like 
structures. In contrast, more then 1.2% of CXR cells 
displayed the ability to form spheroids (Figure 2A, B). 
Statistically, parental cell spheroids were fewer and of 
larger size, when compared to CXR cells (Figure 2B, C). 
CX and GB treatments decreased sphere volumes in 
parental cells (Figure 2C), while in CXR cells did not 
induce effects in terms of either spheroid size or number, 
supporting the lack of sensitivity of these cells to EGFR-
targeting drugs (Figure 2A–C). Next, we investigated 
the morphology of the spheroids both by embedding 
them into paraffin blocks, preparing 8-10 μm slides and 
staining with hematoxylin-eosin (H&E) (Figure 2D) or 
performing confocal microscopy analysis (Figure 2F). 
Parental cells displayed a well-organized architecture, 
with multiple layers of nuclei polarized on the external 
Figure 1: Establishment of colorectal cells resistant to cetuximab. Human colorectal cancer Caco-2 cells were made resistant 
to cetuximab (CX) and gefitinib (GB) by continuous exposure to increasing doses of drug and maintained with 2 μg/ml of CX and 1 μM 
of GB. A. Cell proliferation analysis by Alamar assay of parental, cetuximab-resistant (CXR) and gefitinib-resistant (GBR) cells following 
treatments with increasing concentration of cetuximab in medium containing 1% serum for 72h. The graphic represents the relative 
proliferation/viability of the cells following 72 hours of treatment related to control; B-C. Colony formation assay of parental, cetuximab-
resistant (CXR) and gefitinib-resistant (GBR) cells. Cells were grown in absence or presence of CX (1μg/ml) and GB (1 μM) for 10 days 
in medium containing 1% of serum, then fixed, stained with Crystal Violet and photographed. Representative figures and quantification of 
the covered areas by ImageJ is provided in B and C, respectively. The statistic was calculated by 2-way ANOVA, *** P<0.0001, ** P<0.01. 
These experiments were repeated at least three times. D. Sequence analyses of KRAS Exon 2, showing the wild type sequence detected in 
parental, CXR and GBR cells.
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Figure 2: Cetuximab resistant cells displayed increased ability to growth in suspension as colonspheres. We investigated 
the morphology of Caco-2 parental, CXR and GBR cells when forced to grow in suspension. A. 4X magnification of Caco-2 producing 
“spheroid-like” structures, under the indicated treatments. Scale bar 100μm; B. Number of filled spheroids presented as average ± S.E.M. 
2-way ANOVA with Bonferroni Test, ** p<0.01; ****p<0.0001; C. Quantification of spheroids sizes measurements under the indicated 
treatments in 5% FBS (EGF 10ng/ml, CX 1μg/ml and GB 1μM) is presented as dots plot. Each dot represents the quantification of a single 
spheroid (n= 117 for Parental cells, n=332 for CXR). Bar represents volume averages ± S.E.M, 1-way ANOVA, ** p<0.01; ****p<0.0001; 
D-E. Analysis of Caco-2 parental and CXR paraffin-embedded spheroid morphology by H&E staining. Scale bar 50 μm; F. Single section 
passing through the maximum diameter of spheroids and 3D confocal morphology of parental and CXR spheroids. Left panel: bright 
field imaging; central panels: DAPI and Phalloidin confocal microscopy; right panel: three-dimensional reconstructions of both signals, 
obtained by rotating the y axes and cutting the lower part of the spheroids (green lines) to observe the inner structures; scale bar 100 μm; 
G. Illustration depicting a schematic representation of the parental and CXR spheroid morphology.
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region and a hollow lumen filled with cell debris and 
matrix, as shown in Figure 2D, 2F and illustrated by 
Figure 2G. On the other hand, CXR cells displayed 
poorly organized structures, with sparse nuclei in the 
entire volume and smaller and filled lumen (Figure 2E, F). 
Furthermore, 3D rendering elaboration of the actin and 
nuclei signals, obtained by rotating the y axes and cutting 
the lower part of the spheroids helped to visualize the 
spheroid lumen, which appeared more filled in the 
resistant cells. Summarizing, the CXR cells acquired a 
robust ability to grow in suspension. Parental spheroids 
are well organized and display hollow lumens, whereas 
CXR spheroids are smaller, poorly organized and filled 
or partially filled with cells. These findings support the 
notion that the adaptation to cetuximab leads to resistant 
cells characterized by a more malignant phenotype, which 
enables the cells to grow in suspension.
A module of inflammatory cytokines is induced 
in cetuximab resistant cells
Secreted growth factors and cytokines have been 
shown to contribute to drug resistance by imparting 
compensatory survival cues [16,19,20]. We sought to 
analyse gene expression of parental and resistant Caco-
2 cells, in the presence or absence of cetuximab. The 
analysis included critical components of positive ERBB 
feedback regulatory loops (such as the EGFR ligands 
TGFA, HBEGF), which were recently found to be 
involved in cetuximab resistance [21,22], and of negative 
ERBB feedback loops, namely inhibitors of EGFR/
ERBB signaling, such as LRIG1, LRIG3 and ERRFI1 
[23,24]. To provide further functional annotation, we also 
interrogated markers of the Epithelial to Mesenchymal 
Transition (EMT), such as E-cadherin, vimentin, SNAIL, 
LEF1 and SOX2 (a transcription factor associated 
with stemness) [25]. Finally, we analysed the levels of 
inflammatory cytokines (IL1A, IL1B, IL8), which were 
previously demonstrated to play a role in carcinogenesis 
[26], but whose involvement in resistance to cetuximab 
was not reported. The results are displayed in Figure 3A 
as heat-maps, with red boxes corresponding to relatively 
high expression of the respective transcript and green 
boxes corresponding to low expression. Under monolayer 
conditions, the autocrine ligands HBEGF and TGFA were 
slightly increased upon cetuximab administration and up-
regulated in cetuximab-resistant cells, which also displayed 
increased levels of negative feedback regulators (Figure 
3A). In addition, resistant cells also featured increased 
levels of markers of epithelial-mesenchymal transition 
and stem-like features, with reduced expression of CDH1 
(E-cadherin) and increased expression of vimentin, the 
EMT inducer SNAIL, and the stem-cell transcription 
factors LEF1 and SOX2 (Figure 3A). Finally, EGFR 
inhibition by cetuximab in parental cells led to a slight 
increase in expression of IL1A, IL1B and IL8; and these 
cytokines were markedly overexpressed in cetuximab-
resistant cells (Figure 3A). Most of the transcriptional 
modulations that occurred in 2D resistant cells could 
be also observed in resistant spheroids (Figure 3B), 
indicating maintenance of these traits irrespective of 
culture conditions. Acquired production of the positive 
feedback components, such as HBEGF and simultaneous 
inhibition of EGFR by negative feedback might reflect a 
shift toward HER2 heterodimer activation, as previously 
reported [15,27]. Of note, spheroids from parental 
cells did not experience any obvious transcriptional 
reprogramming following exposure to cetuximab, apart 
from increased expression of some EGFR negative 
regulators. The weak transcriptional consequences of 
EGFR blockade in parental spheroids could be related 
to initial selection of cells growing in suspension, which 
might have enriched for cells that are more resistant to 
pro-apoptotic insults, including anchorage-independent 
growth and EGFR blockade. Analyses of the signalling 
pathways downstream to EGFR helped us to characterize 
signalling differences between parental and CXR cells. 
Indeed, while parental cells responded to CX treatment, 
by decreasing both phosphorylation of AKT and ERK 
(Figure 3C), resistant cells appeared not sensitive to CX 
inhibition on AKT phosphorylation. Interestingly the 
basal level of pERK was in general higher in resistant 
cells, and CX still displayed inhibitory capability on 
pERK, although less effective (Figure 3C). Collectively, 
this analysis shows that the resistant phenotype is 
accompanied by increased expression of inflammatory 
cytokines and EGF-like growth factors, feedback 
activation of EGFR negative regulators, and EMT/stem-
like features. These data are further supported by the 
evidence that EGFR activation in epithelial cells, such as 
MCF10A human mammary cells, immediately produces a 
module of inflammatory cytokines, namely IL1B, IL8 and 
CXCL1, by active transcriptional production (Figure 4A). 
MCF10A cells are highly dependent on EGFR pathway, 
thus it represents a useful tool to study EGFR signalling, 
avoiding perturbations derived from tumor transformation. 
Furthermore, co-treatment with Dexamethasone (DEX), 
a global inhibitor of the EGFR transcriptional response 
[7,28], dampened this production, pointing to a direct 
involvement of the EGFR pathway in the transcriptional 
induction of inflammatory mediators (Figure 4A). Because 
EGF simultaneously up-regulated several inflammatory 
cytokines and because this effect was abrogated by DEX, 
which is a powerful anti-inflammatory agent mainly 
acting through repression of NF-κB [29], we assumed 
that the inflammation-regulating transcription factor NF-
κB is activated by EGF in mammary epithelial cells. In 
line with this model, we observed a dose-dependent 
activation of NF-κB (p65) by EGF (Figure 4B). To extend 
these observations to the protein level and also to assay 
additional cytokines, we utilized a cytokine array (Figure 
4C, D). This analysis detected high basal levels of IL1A 
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in untreated cells, which was increased following EGF 
stimulation and dampened by the DEX co-treatment. 
Interestingly, IL1B, IL8 and CXCL1 displayed very low 
basal levels with strong induction upon the growth factor 
stimulus, and once again the anti-inflammatory action of 
DEX was able to block production of these cytokines, in 
line with our previous observations [7].
Secreted factors from cetuximab resistant cells 
are causally involved in sustaining resistance to 
cetuximab
To analyse if changes in factors secreted from 
resistant cells are causally involved in sustaining 
resistance, we first tested the cetuximab efficacy on 
Figure 3: Gene expression analysis of parental and CXR cells. A-B. PCR analysis of parental or cetuximab resistant (CXR) 
cells growing as monolayer (A) or as spheroids (B) were collected, both under CX (2μg/ml) treatment or regular medium conditions. A 
set of genes probing EGFR positive/negative feedback loop, EMT phenotype and inflammatory cytokines were analysed and displayed as 
heatmap. C. Western blot analysis of phospho-AKT (pAKT), AKT, phospho-ERK (pERK) and ERK levels in Caco-2 parental and CXR 
cells treated over-night with and without cetuximab. Actin served as a loading control.
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spheroidogenesis and colony formation ability following 
administration of conditioned media (CM) from cetuximab 
resistant cells (CMR) (Figure 5A). The CM from CXR 
cells, hereinafter referred as CMR, displayed effect both 
on spheroids number and size, promoting a six-fold 
increase in number (Figure 5B) and two-fold increase in 
sphere dimension (Figure 5C). Administration of CMR 
to resistant cells also increased spheroidogenesis in 
Figure 4: EGFR activation controls the production of a module of inflammatory cytokines in MCF10A. A. Expression 
levels of the module of inflammatory cytokines (IL1B and IL8 and CXCL1) analysed by Real-Time PCR in MCF10A following EGF (10ng/
ml) or DEX (100nM) administration, alone or in combination, over a time course of 4h; B. Western blot of NF-kB in cytoplasmic and 
nuclear fraction of MCF10A cells following administration of increasing doses of EGF (from 1 to 100ng/ml). TNFα (1ng/ml) treatment 
was used as positive control for NF-kB (p65) activation and nuclear translocation. Laminin B and HSP90 were used as loading control for 
the nuclear and cytosolic fraction, respectively; C-D. Cytokine array of MCF10A cells following administration of EGF (10ng/ml), DEX 
(100nM), alone or in combination. Representative pictures are provided in C. Quantification of chemioluminescence along with images of 
normalized spots are provided in D.
Oncotarget72174www.impactjournals.com/oncotarget
terms of number (Figure 5B), but not in terms of volume 
(Figure 5C). We further tested the response to cetuximab 
in the presence of conditioned medium from resistant 
cells in a colony forming assay. Again, by measuring 
the clonogenic proliferation by crystal violet staining, 
the inhibitory ability of cetuximab was impaired by 
60% when parental cells were kept in the presence of 
CMR (Figure 5D). Finally, we collected the conditioned 
medium both from parental (CMP) and CXR cells (CMR), 
as depicted in Figure 5F. The proliferation experiments 
in these conditions show that the efficacy of CX is 
maintained when combined with conditioned medium 
collected from parental cells. In contrast, simultaneous 
administration of conditioned medium from CXR cells 
reduced the inhibitory activity of cetuximab on cell 
proliferation (Figure 5F).
All these data pointed to the presence of secreted 
molecules from CXR cells to the CM, which decreased 
cetuximab efficacy and acted as strong mitogenic stimuli. 
Interestingly, the conditioned medium of parental cells did 
not affect cetuximab response in sensitive cells; suggesting 
that soluble molecules specifically secreted by CXR cells 
are sufficient to overcome the response to cetuximab in 
otherwise sensitive cells.
Next we tested whether the clonogenic property 
induced by CMR was mediated by the activation of 
NF-κB. Indeed, NF-κB is a well-known hub mediator 
for inflammation and tumor growth. We employed 
parthenolide, a natural NF-κB inhibitor, previously 
reported to inhibit mammospheres formation induced by 
TNF-alpha [30]. Parthenolide treatment decreased the 
colonspheres forming capacity of parental cells growing 
under regular medium (Figure 5G, H). Importantly, 
parthenolide was able to prevent the spheroidogenesis 
induced by CMR conditioned medium (Figure 5I, J). 
These results support the hypothesis that NF-kB is a key 
player in resistance to CX treatment, likely for its ability 
of inducing pro-inflammatory cytokines production (such 
as IL1A, IL1B and IL8), which in turn activates a NF-κB 
dependent feed-forward loop, as reported in pancreatic 
tumors [31].
A module of inflammatory cytokines predicts 
resistance to cetuximab in colorectal patients
Our data in vitro pointed out the increased 
expression of a panel of inflammatory cytokines in cells 
resistant to cetuximab. We therefore decided to analyse 
the panel of selected cytokines in patients colorectal 
tumorgraft. Gene expression information was analysed 
in colorectal tumorgrafts from 98 patients with wild 
type KRAS, BRAF, NRAS, and PIK3CA genotypes 
Figure 5: Secreted factors from CX resistant cells reduces cetuximab sensitivity on parental cells. A. Schematic diagram 
showing the modality of obtaining conditioned medium from CXR cells (CMR), which was subsequently used for treatments. CMR was 
collected from CXR Caco2 cells cultured for 72h in presence of cetuximab (2 μg/ml); B-C. Spheroid assay of parental and CXR cells 
cultured in fresh medium or CMR, both supplemented with EGF (10 ng/ml) and cetuximab (2 μg/ml). Pictures at 4x magnification of at 
least four not overlapping fields were taken after 10 days and spheroids number and volume were measured. Quantification of spheroids 
number (mean ± s.e.m) is provided in B. Quantification of volume of each spheroid and the mean value for each treatment is provided in C. 
* p< 0.05 **** p< 0.0001, n.s.: not significant (two-way ANOVA); D. Colony formation assay of parental cells seeded with fresh medium 
or conditioned medium from CXR cells (CMR), both supplemented with Cetuximab (2 μg/ml). Representative images of crystal violet 
staining are provided in the left panel. Quantification of the relative covered area, displayed as percentage of conditioned medium treatment 
(mean ± s.e.m), is provided in the right panel. p<0.00026 (t-test). (Continued )
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(“quadruple negative” tumors) and from 61 individuals 
with KRAS (G12) mutation. KRAS G12 mutation leads 
to a constitutively activated K-Ras protein, which confers 
an intrinsic resistance to EGFR blockade. WT quadruple 
negative tumorgrafts were tested for cetuximab response, 
as described by Bertotti [32]. In this condition, the 
human stroma is supposed to be substituted by murine 
components; therefore, this analysis covers only 
receptors and autocrine ligands expressed by cancer cells. 
Interestingly, we observed an inverse association between 
elevation of inflammatory cytokines IL1A, IL1B and IL8 
and the overall response to cetuximab (Figure 6A). In 
accordance with our in vitro data, IL1A, IL1B and IL8 
were overexpressed in tumorgrafts that proved to be 
resistant to EGFR blockade (tumor volume increase 
of at least 35% compared to the initial, pre-treatment 
volume). Furthermore, intermediate IL8 expression 
levels were observed in a group with limited sensitivity 
to cetuximab, with tumour volume changes between 
35% increase and 50% reduction, which is considered 
Figure 5: (Continued ) Secreted factors from CX resistant cells reduces cetuximab sensitivity on parental cells. E. Scheme 
depicting the second modality of conditioned media production from Parental or CXR Caco-2 cells. In these settings the conditioned media 
was collected from parental and CXR cells cultured for 72 hours in full medium supplemented with EGF (10 ng/ml) alone or in combination 
with cetuximab (2 μg/ml); F. Parental and CXR cells were treated with the conditioned medium obtained as described in E. Cell growth/
viability was measured with Alamar blue assay after 96 hours (in the graph mean ± s.e.m, arbitrary unit). ** p<0.01, n.s.: not significant 
(two-way ANOVA). G-H. Spheroid assay of parental cells cultured in fresh medium, supplemented with EGF (10 ng/ml) and cetuximab (2 
μg/ml) plus parthenolide (1μM). Pictures at 4x magnification of at least four not overlapping fields were taken after 10 days and spheroids 
number and volume were measured. Quantification of spheroids number (mean ± s.e.m) is provided in G. Quantification of spheroid 
volumes along with the mean value for each treatment is provided in H. ** p< 0.01 **** p< 0.0001 (one -way ANOVA); I-J. Spheroid 
assay of parental cells cultured in fresh medium, or conditioned medium from CXR cells (CMR) supplemented with EGF (10 ng/ml) and 
cetuximab (2 μg/ml), alone or in combination with parthenolide (10 μM). Pictures at 4x magnification of at least four not overlapping 
fields were taken after 10 days and spheroids number and volume were measured. Quantification of spheroids number (mean ± s.e.m) and 
volumes is provided in I and J, respectively. * p< 0.05 ** p< 0.01 **** p< 0.0001 (one -way ANOVA).
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as stable disease (SD) (Figure 6A, B). Interestingly, 
the pattern of increased expression of this module of 
inflammatory cytokines was maintained in the group of 
KRAS mutant tumours, which by definition are resistant 
to treatment. These results suggest that gradual tumour 
adaptation to EGFR blockade might be associated with 
up-regulation of the module of inflammatory cytokines, 
which might be responsible for tumor plasticity and 
activation of compensatory pathway, thus overcoming 
EGFR inhibition.
Figure 6: A panel of inflammatory cytokines correlates with cetuximab response in colorectal patients. A. Expression 
analysis of IL1A, IL1B and IL8 in colorectal quadruple wild type (wild type for KRAS, BRAF, NRAS and PIK3CA) tumors, subdivided by 
response to Cetuximab therapy: disease regression (PR), disease stabilization (SD), disease progression (PD). The KRAS (G12 Mut) group 
was included as control for lack of response to CX; B. Forest plot summarizing the differences between the indicated groups in the data set 
of colon cancer patients. Each line represents the 95% confidence interval corresponding to the listed comparisons. Note that the red lines 
indicate statistical significance; C. RNAseq data of colon cancer samples from TCGA Colorectal Adenocarcinoma (631 samples from 627 
patients). D-E. Co-expression analysis from TGCA datasets, of IL1A and IL1B (D) and of IL8 and IL1B (E). Statistically significant values 
were computed and Pearson and Spearman correlation values are provided.
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We next tested the expression of the module of the 
identified cytokines IL1A, IL1B and IL8 on data generated 
by the TCGA Research Network (http://cancergenome.nih.
gov/), which encompasses 631 patients’ tumour samples. 
Specifically, we interrogated the Colorectal Adenocarcinoma 
subset (TGCA Provisional) and filtered mRNA expression 
levels with reported expression z-Scores (RNA Vs RSEM) 
>= 1.5, as normalized against the expression distribution 
of all gene tumours that are diploid for the corresponding 
gene. By doing so, we identified about 11% of tumors 
(67 out of 631 samples) displaying an alteration on the 
probed cytokines panel (Figure 6C). We also interrogated 
the co-expression of the reported genes on the same data 
set (17157 genes from 244 colorectal adenocarcinoma 
cases); strikingly, IL1B, IL8 and CXCL1 display the highest 
correlation with IL1A, with a Pearson correlation of 0.66, 
0.55 and 0.51 respectively. We also observed a correlation 
between IL1B and IL8 (Figure 6E), which reaches the 
highly significant value of 0.78 Pearson and 0.81 Spearman. 
These data suggest a common regulation of the reported 
cytokines, which might be driven by shared regulators, such 
as the inflammatory Transcription Factor NF-κB. To sum 
up, these results propose that about 11 % of the colon cancer 
population might benefit by intercepting NF-κB along with 
the detected cytokines. Notably, TGCA data show a lack of 
correlations of the reported cytokines with KRAS mutation 
and our in vitro model confirms a RAS wild-type status in 
the resistant condition.
DISCUSSION
Our study points to the production of soluble 
cytokines IL1A, IL1B and IL8, as markers of a poor 
response to cetuximab and as potential key factors in 
CRC tumor adaptation to cetuximab pressure. These data 
suggest to evaluate this panel of inflammatory cytokines 
in patients’ tumour specimens before initiating EGFR-
treatment, since it could represent an additional criteria 
predicting therapy efficacy.
It is notable that cetuximab appears to be more 
effective than EGFR TKIs in cancers with ligand-
dependent activation of EGFR, whereas TKIs are more 
effective in cancers with EGFR mutations. Cetuximab 
might block and compete with the ligands production 
[33]. Hence, in colon cancer the autocrine/paracrine 
action of soluble growth factors might have a central role 
in mediating drug response [34]. Our study indicates a 
new mechanism of resistance to cetuximab in mCRC that 
relies on autocrine or paracrine production and secretion 
of inflammatory cytokines (Figure 7). Moreover resistant 
cells display cellular plasticity toward an undifferentiated 
phenotype, lacking E-cadherin and featuring strong up-
regulation of vimentin and SNAIL.
Recently, it has been suggested that mutated KRAS 
clones may emerge in patients during cetuximab treatment 
over time, thus providing a rationale to understand cancer 
cell resistance to cetuximab [35]. Interestingly, RAS 
Figure 7: Model depicting the link between the unveiled inflammatory cytokines and resistance to cetuximab. Schematic 
diagram showing a new mechanism of resistance to cetuximab in colorectal cancer, relying on autocrine or paracrine production and 
secretion of the inflammatory cytokines IL1A, IL1B and IL8. Under EGFR targeting, colorectal tumors might display rewiring of cell 
signalling with consequent undifferentiated phenotype and activation of the indicated cytokines along with NF-kB signalling.
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dependent activation of NF-κB might be responsible for 
the production of several cytokines [36]. Therefore the 
increase in IL1A, IL1B and IL8 in resistant cells might 
represent emergence of the KRAS-mutation. Nevertheless, 
the sequencing analysis confirmed a KRAS wild type 
status of our resistant cells, which might suggest that NF-
κB activation and cytokines production occurrence is an 
epiphenomenon, responsible for activation of alternative 
signalling routes, thus overcoming drug response. The 
unveiled promotion of a surrounding microenvironment 
enriched in pro-inflammatory cytokines capable of 
impairing the cetuximab response in otherwise sensitive 
cells, certainly represents an emerging link between EGFR 
and cytokine signalling in colon cancer. These findings are 
in line with the detection of the rapid engaging of NF-κB 
signalling upon EGFR inhibitor treatment, which in lung 
cancer was proved to promote cell survival and resistance 
to treatment [37]. Importantly, our data clearly show that 
patients with an alteration in the panel of pro-inflammatory 
cytokines are not sensitive to cetuximab treatment, 
recapitulating the trend of KRAS resistant patients. Notably, 
the administration of IL1 receptor antagonist (Anakinra), 
in combination with Bevacizumab for mCRC, is currently 
under evaluation in clinical trial (NCT02090101). Further, 
IL1A inhibition, by mean of a true humanized antibody 
(MABp1), showed promising results in refractory cancers 
[38]. Therefore, blocking these cytokines in combination 
with EGFR targeting agents might represent a promising 
therapeutic strategy for colorectal cancer patients. To sum 
up, these data point to a new approach to treat colorectal 
patients that poorly respond to EGFR targeted therapies. 
Indeed, the inhibition of the inflammatory cytokines might 
push the cells towards a new steady state, sensitive for the 
EGFR inhibition.
MATERIALS AND METHODS
Cell lines and establishment of resistant cells
Caco-2 cells were maintained in DMEM 
supplemented with 10% fetal bovine serum and 1% Pen/
Strep. Caco-2 were cultured adding cetuximab (Erbitux, 
Merck KgaA, Germany) and gefitinib (ZD1839 Astra 
Zeneca) at increasing concentrations, up to 10 μg/ml and 
10 μM respectively, for a few months, till the resistant 
cells were established. Cetuximab-resistant cells (CXR) 
were then maintained in culture with cetuximab (2 μg/ml) 
and gefitinib-resistant cells (GBR) with gefitinib (1 μM). 
Parthenolide was purchased from SIGMA, P0667 and 
diluted in DMSO.
Cells were routinely tested for mycoplasma 
contamination. MCF10A were kindly provided by Yosef 
Yarden Laboratories. MCF10A cells were cultured with 
DMEM/F12 medium (GE Healthcare) as previously 
described [39] supplemented with 10 μg/ml Insulin (I6634, 
Sigma), 0.5 μg/ml Cholera Toxin (C8052, Sigma), 0.5 μg/
ml hydrocortisone (H0888, Sigma), 5% heat inactivated 
horse serum and 10ng/ml EGF (E9644, SIGMA). The 
cells were serum-starved overnight in plain medium and 
thereafter treated with EGF (10 ng/ml).
Proliferation assay
Cells were seeded in 96-well plates, 2.000 cells for 
each well, in 100μl of 5% FBS medium. Quantification of 
initial time (time 0) was performed the following day using 
Alamar Blue (20 μM) in medium 0% FBS, measuring the 
fluorescence after 5 hours of incubation. Fluorescence 
was quantified using VICTOR2
TM
 1420 multilabel counter 
(Perkin Elmer, Massachusetts, USA), at a wavelength 
of 595 nm. Cells were then treated according to the 
experiment and, after 72-96h proliferation was measured 
using Alamar Blue, following the same procedure. Data 
were analysed subtracting background values, normalizing 
the endpoint values on the initial time ones, calculating 
for each treatment the median value and transforming it as 
percentage of the untreated control. Data points represent 
the median +/- SD. Each experiment was repeated at least 
three times.
Colony forming assay
2.000 cells were seeded in 12-well plates in 1 ml 
of medium. Treatments were added immediately or the 
following day, according to the information included in 
the figure legends. After two weeks, the medium was 
removed, and the cells were washed with PBS and fixed 
with a solution of methanol and acetone 1:1 for 20 minutes 
at -20°C. After a washing with PBS, the cells were stained 
with Crystal Violet 0.5% for 30 minutes, then were 
washed with water to remove excess dye. A picture of 
each well was taken and the covered area was measured 
using ImageJ software. The mean value from covered area 
values returned by the software was calculated for each 
treatments and recorded as a percentage of control. Each 
experiment was repeated at least three times.
Spheroid assay
To inhibit cellular adhesion to the plastic surface, 
6-well plates were covered with a layer of agar 0.6%. 
Agar 1.8% was autoclaved and diluted to 0.6% with full 
medium; 1.5 ml of 0.6% agar was used to cover each well 
and the agar layer was left to dry before seeding cells. 
5.000 or 10.000 cells were seeded for each well in 2 ml 
of 5% FBS medium, supplemented with EGF (10 ng/
ml). Treatments were added immediately or the following 
day, according to the information included in the figure 
legends. After 10 days of treatment, pictures of four non-
overlapping fields for each well were collected using 
the microscope at 4X magnification. Spheroids of each 
picture were counted, and the length of the major and 
minor axis of each spheroid was measured using ImageJ 
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Software. Axis values below 70 A.I. were excluded as 
not corresponding to mature spheroids and volume was 
calculated applying the sphere adapted formula (major 
axis x minor axis)2/2. Each experiment was repeated at 
least three times.
Spheroids sections and hematoxylin-eosin 
staining
Spheroids from 3D culture were collected, 
centrifuged and medium was removed. After PBS 
washing, spheroids were fixed in formalin 4% for an 
hour and washed with water. Spheroids were dehydrated 
with successive steps of five minutes at increasing 
concentrations of ethanol (70°, 80°, 95°, 100°) then passed 
twice in xylene for 30 minutes. After drying, the pellet 
was embedded in paraffin. Sections of 8-10 μm were cut 
and put on a slide. After overnight at 62° in a dry stove, 
sections were rehydrated with successive steps of five 
minutes at decreasing concentrations of ethanol (100°, 
95°, 80°, 70°) and washed with water. They were stained 
with hematoxylin (Carazzi Emallume) and eosin for 10 
and 5 minutes, respectively. Sections were dehydrated as 
spheroids as above and passed three times in xylene for 
5 minutes. Cover slip were applied using DXP mounting 
media and left to dry. Pictures at 4x and 10x were collected 
by Microscope Leica DM750.
Confocal microscopy
Spheroids from 3D culture were collected, 
centrifuged and medium was discarded. After 
PBS washing, spheroids were fixed with ice cold 
acetone:methanol (1:1) for 20 min. The spheres were then 
placed on Fluorodish Cell Culture Dishes, with optical 
quality glass bottom and directly stained with 50 μg/
ml Phalloidin-TRITC Ab (Sigma, P1951) and 0.1μg/ml 
4’,6-Diamidino-2-phenylindole (DAPI, Sigma, D9542). 
The confocal imaging was performed with a Nikon A1-R 
confocal laser scanning microscope, equipped with a 20× 
0.7 NA objective and with 405 and 561 nm laser lines to 
excite DAPI and TRITC fluorescence signals. Confocal 
images (resolution: 1024 × 1024 pixels; gray levels: 4096) 
were obtained by optical sections of the central region of 
the spheroids. Volume view with 3D rendering was carried 
out using the NIS Elements Advanced Research software 
(Nikon).
Western blot
Caco-2 cells were lysed with Novagen 
PhosphoSafe Extraction Reagent (EMD Millipore) 
plus Protease Inhibitors Cocktail (Sigma-Aldrich) and 
incubated for 10 minutes on ice. Protein concentration 
in the supernatants was determined by DC Protein 
Assay (Bio-Rad) using bovine serum albumin as the 
standard. Proteins (15 μg of total lysate) were separated 
on 8% polyacrylamide gel and then transferred to 
polyvinylidene difluoride membranes (Bio-Rad). After 
blocking with TBS containing 0.1% tween 20 plus 
5% non-fat dry milk (Bio-Rad) for one hour at room 
temperature, membranes were incubated overnight at 
4°C with primary antibodies diluted in blocking buffer. 
The following primary antibodies were used: anti-AKT 
rabbit polyclonal antibody (1:1000 dilution; #9272, 
Cell Signaling), anti-phospho-AKT (Ser473) (D9E) 
XP rabbit monoclonal antibody (1:1000 dilution; 
#4060, Cell Signaling), anti-p44/42 MAPK (Erk1/2) 
(137F5) rabbit monoclonal antibody (1:1000 dilution; 
#4695, Cell Signaling), anti-phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) rabbit polyclonal antibody 
(1:1000 dilution; #9101, Cell Signaling) (all from Cell 
Signaling Technology) and anti-actin rabbit polyclonal 
antibody (1:800; A2066, Sigma Aldrich). Protein 
presence was detected through the incubation with 
anti-rabbit horseradish peroxidase-labeled secondary 
antibody (Santa Cruz Biotechnology) followed by 
chemiluminescent reaction (Clarity Western ECL 
Substrate, Bio-Rad).
Conditioned medium collection
500.000 Caco-2 parental and CXR were cultured in 
3 ml of full medium supplemented with EGF (10 ng/ml) or 
cetuximab (2 μg/ml), alone or in combination (according 
to the figure legends) for 72 hours. Four different 
conditioned mediums were then collected, centrifuged at 
500g for 5 min to remove death cells and debris and used 
for treatments. Each experiment was repeated at least three 
times.
Nuclear-cytoplasm fractionation
Cells were harvested in hypotonic buffer (10 mM 
HEPES pH 7.9, 1.5 MgCl
2
, 10 mM KCl, 0.5 mM DTT, 
0.5% NP40 and 1 mM sodium vanadate) containing a 
mixture of protease inhibitors. Nuclei were centrifuged at 
12.000 at 4°C for 15 minutes and re-suspended in lysis 
buffer, followed by a sonication step.
Cytokine arrays
Human Cytokine Array (R&D Systems, 
Minneapolis, MN) and chemiluminescence detection 
reagents were used, and signals were normalized to the 
loading control.
MCF10A cells were starved overnight for growth 
factors and thereafter treated for 4 hours with EGF 
(10ng/ml), dexamethasone, DEX (100nM), alone or 
in combination. Whole cell lysates were collected and 
spotted on cytokine arrays, following manufacturer’s 
instructions. Chemiluminescence detection reagents were 
used to visualize and quantify cytokine levels.
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RNA Isolation and qPCR
RNA was extracted using TRIZOL® Reagent 
(Invitrogen, Life Technologies), chloroform for separation 
of three phases, isopropanol for RNA precipitation and 
ethanol 75% for washing. RNA was resuspended in DEPC 
water. Total RNA quantity and quality were determined 
using a NanoDropTM Spectrophotometer (Thermo 
Fischer Scientific, Waltham, MA, USA). RNA quality 
was also evaluated with agarose gel 1% electrophoresis, 
visualizing bands, stained with ethidium bromide, 
through a Geldoc transilluminator (Biorad, California, 
USA). cDNA was synthesized using a retrotranscription 
mix consisting of buffer 5x (Thermo Fischer Scientific, 
Waltham, MA, USA), dNTP mix 1 mM, oligo dT 5 μM, 
random examer 5 μM, RiboLock RNAse inhibitor 1 U/
μl, RevertAid RT (Thermo Fischer Scientific, Waltham, 
MA, USA) 0,5 U/μl and water, and incubating for the 
reaction in a Thermal Cycler (VWR, Pennsylvania, USA). 
Real-time qPCR analysis was performed with MaximaTM 
SYBR Green qPCR Master Mix 2X (Fermentas, Thermo 
Fischer Scientific) in C1000
TM
 Thermal Cycler (Biorad, 
California, USA); the primer list is shown. qPCR signals 
(CT) were normalized to beta2-microglobulin (B2M), 
DDCT was calculated and each gene value was linearized 
to the time zero using the formula 2^-DDCT. Each qPCR 
run always included a negative control lacking cDNA 
template, and a positive control of cDNA derived from 
the HT-29 cell line, which express the gene of interest. 
Reaction efficiency (E) was calculated from the slope of 
the standard curve generated from 10-fold serial dilutions 
of calibrator cDNA, according to the formula: E = [10 
(−1/slope)−1] × 100. At the end, B2M normalized data 
were median centered using Cluster software and the 
unsupervised hierarchical clustering was generated with 
Euclidean distance as similarity metric followed by 
complete linkage and finally visualized as a heatmap using 
Java Tree View software.
Primer list
Gene Nam 5′->3′ Amplicon Bp
FH_CDH1 CAGTACAACGACCCAACCCA 135
RH_CDH1 CACGCTGACCTCTAAGGTGG














FH_IL1 A TCTGCACTTGTGATCATGGTTT 72
RH_IL1 A CACATTGCTCAGGAAGCTAAAAG







The statistical analyses were performed by using Prism 
version 6 (GraphPad Sotfware, Inc). The one way or two-way 
ANOVA were used to test significance of the assays.
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